Home

Part of our AI Trading ecosystem

AI Trading Tool

The main AI trading tool page

AI Stock Analysis

4,600+ stocks analyzed

AI Stock Picks

Daily AI-generated picks

AI Stock Picker

Scan the universe for ideas

Stock Recommendations

Ranked AI research ideas

AI Trading Signals

Real-time momentum alerts

AI Stock Screener

Scan 4,600+ stocks live

Best AI Trading Tools

#1 pick: Stockinhood

How AI Trading Works

The technology explained

AI Stock Predictions

Multi-timeframe targets

BRTM

Neutral

B&R Technology Merger Corp.

Financial Services·Shell Companies

$9.87

Current Price

$482.6M

Market Cap

—

P/E Ratio

$10.25

52W High

$9.78

52W Low

Company Profile

CEO

Not Disclosed

Employees

2

Year Founded

2026

Headquarters

New York, NY

Sector / Industry

Financial Services · Shell Companies

Key Statistics

Market Cap

$482.6M

Today's High

$9.90

Today's Low

$9.85

Open

$9.86

Previous Close

$9.87

52-Week High

$10.25

52-Week Low

$9.78

Today's Volume

15.4K

Avg. Volume

32.16K

Overnight Volume

1.2K

Shares Outstanding

48.9M

P/E Ratio

0.00

EPS

$0.00

Beta

0.05

Dividend Yield

0.0%

Live market stats are a premium feature

These stats are from a cached snapshot. Unlock real-time data with lifetime access — $19.99.

Earnings History

Quarterly expected vs. actual performance

Q2 20262026-08-14
Beat
EPS Est.0.00
EPS Actual0.00
Rev. Est.$0.00
Rev. Actual$0.00
Q1 20262026-05-15
Beat
EPS Est.0.00
EPS Actual0.00
Rev. Est.$0.00
Rev. Actual$0.00
Q4 20252026-02-20
Beat
EPS Est.0.00
EPS Actual0.00
Rev. Est.$0.00
Rev. Actual$0.00
Q3 20252025-11-14
Beat
EPS Est.0.00
EPS Actual0.00
Rev. Est.$0.00
Rev. Actual$0.00

Earnings data is AI-compiled from public sources and may be delayed or approximate. Not financial advice.

Historical Price Chart

Price History

Chart data unavailable

AI Price Targets

B&R Technology Merger Corp. (BRTM) is a newly formed Special Purpose Acquisition Company (SPAC) targeting opportunities in the technology sector. The company completed its initial public offering in mid-2026 and began separate trading of ordinary shares and warrants in September 2026. Because SPACs trade near their redemption trust value until a business combination is announced and completed, the price action remains rangebound between $9.78 and $10.25. The technical and fundamental stance remains neutral until a target merger candidate is identified.

7-Day Target

$9.90

+0.3%

30-Day Target

$10.05

+1.8%

6-Month Target

$10.25

+3.9%

AI Confidence

60%

Risk Level

Medium

Analyst Target

$8.5

Bull Case

The successful advancement of VTP-300 for chronic hepatitis B treatment could create a massive commercial opportunity in a large, underserved market, validating their core T cell induction platform.

Bear Case

The company faces significant clinical execution risk and cash burn concerns, as most of its pipeline remains in early-to-mid-stage development with no commercialized products.

Key Catalysts

  • Readouts from ongoing VTP-300 phase 2 studies
  • Strategic partnership agreements for clinical development
  • Advancement of the VTP-1000 preclinical autoimmunity program
  • Regulatory updates from the FDA or EMA on clinical trial designs

Key Risks

  • •High cash burn rate requiring potential dilutive financing
  • •Clinical trial failures for lead candidates
  • •Intense competition in the infectious disease and immunotherapy sectors
  • •Regulatory uncertainty regarding novel T cell therapy platforms

Company Overview

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel T cell-based immunotherapeutic candidates. Its pipeline utilizes proprietary platforms, such as Vax-iNATE, to address chronic infectious diseases, autoimmunity, and oncology.

Take this research further — free

Open BRTM in the full AI tools and run your own analysis: live charts, 7-day to 6-month targets, and risk checks. 15 minutes free, no card required.

Rather have it all, permanently?

30-day money-back guarantee • Secure payment by Square

BRTM Stock FAQ

What is the AI analysis for BRTM stock?

Stockinhood's AI generates multi-timeframe price targets for BRTM (B&R Technology Merger Corp.), including 7-day, 30-day, and 6-month outlooks based on market data, technical indicators, and news sentiment. These estimates are for informational purposes only and do not constitute financial advice.

Is BRTM stock a good investment?

Our AI assigns a sentiment signal (Bullish, Bearish, or Neutral) to BRTM based on multiple factors including price trends, momentum, and market conditions. The current AI signal is Neutral. This is AI-generated research, not financial advice — always consult a licensed advisor before investing.

What is the price target for BRTM?

The AI-generated price target for BRTM is based on multi-timeframe analysis and represents a hypothetical scenario, not a guarantee. The current price is $9.87. Price targets are educational estimates and should not be relied upon for investment decisions.

What are the risks of investing in BRTM?

High cash burn rate requiring potential dilutive financing Clinical trial failures for lead candidates Intense competition in the infectious disease and immunotherapy sectors Regulatory uncertainty regarding novel T cell therapy platforms All risk analysis is informational only and not financial advice.

What sector is BRTM in?

B&R Technology Merger Corp. (BRTM) operates in the Financial Services sector, specifically the Shell Companies industry. This classification helps investors understand the company's business focus and compare it with peers in the same sector.